AME vs URGN · P/E 30, rev $2.04B vs rev $109.8M
Ametek Inc (AME) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
Ametek Inc (AME) is a specialty industrial machinery company listed on US.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported AME revenue for 2026-06-30 was $2.04B. Net income was $406.9M. Revenue was up 6.0% from 2026-03-31 to 2026-06-30. AME currently screens at market cap $42.11B and trailing P/E 29.9.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
AME currently screens at market cap $42.11B and trailing P/E 29.9. URGN currently screens at market cap $1.61B.
Not investment advice. Open the AME and URGN stock pages for the full models.
Not investment advice.